

19 September 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

Rights Issue Closure and Shortfall Notification

Optiscan's fully underwritten pro-rata renounceable entitlement offer to raise \$17.75m to fund the next stage of its strategic transformation to a medical device manufacturer and digital healthcare solution provider closed on 16 September 2025.

Optiscan Imaging Limited (ASX: OIL) ('Optiscan' or the 'Company') is pleased to announce that its fully underwritten pro-rata renounceable entitlement offer of one (1) fully paid ordinary share (**Share**) for every four (4) shares held on the Record Date at an issue price of \$0.085 per share to raise approximately \$17,750,992 (before costs) closed at 5.00pm (AEST) on Tuesday, 16th September 2025.

The offer was strongly supported with valid applications. Final results were as follows:

	Funds raised	Shares
Entitlements applied for through the Offer	\$9,809,000.85	115,400,004
Shares applied for by eligible shareholders through the shortfall	\$155,768.61	1,832,572
Sub total	\$9,964,768.96	117,232,576
Remaining shortfall to be allocated to underwriter	\$7,786,276.51	91,603,253
Total	\$17,617,830.49	207,268,594

Substantial shareholder, Peters Investments Pty Ltd, acted as Underwriter to the Offer. Optiscan has notified the Underwriter of the Shortfall. The Company anticipates that it will issue and allot all new Shares under the Offer on Tuesday, 23 September 2025.

The Board would like to express appreciation to participating shareholders for their ongoing support of the Company.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
 Optiscan Imaging Ltd
 Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
 The Capital Network
 Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.